NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Bologna, Italy. In Cancer, Feb 2016
Six of 27 PTCs (22%) had ret proto-oncogene (RET) fusions (RET/PTC1, n = 5; RET/PTC3, n = 1); 2 tumors measured >2 cm and diffusely involved the thyroid, and 5 had lymphatic invasion, with vascular invasion in 2. Thirteen PTCs had the B-Raf proto-oncogene, serine/threonine kinase (BRAF) valine-to-glutamic acid mutation at position 600 (BRAF(V) (600E) ) (13 of 27 tumors; 48%), 11 measured <2 cm, and 6 had lymphatic invasion (46%), with vascular invasion in 3. Fusion oncogene tumors, compared with BRAF(V) (600E) PTCs, were associated with large size (mean, 2.2 cm vs 1.5 cm, respectively; P = .05),
Current Therapeutic Options in Sturge-Weber Syndrome.
Baltimore, United States. In Semin Pediatr Neurol, Dec 2015
The mutation results in constitutive overactivation of the Ras-Raf-MEK-ERK and the HIPPO-YAP pathways and inhibitors of these pathways may in the future prove useful in the treatment of Sturge-Weber syndrome.
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
Milwaukee, United States. In Semin Oncol, Dec 2015
Aberrant activation of the three-layered protein kinase cascade, Raf/MEK/ERK, is often detected in human cancer, which is mainly attributed to the oncogenic alterations of RAF, or its upstream activators RAS or cell surface receptor tyrosine kinases.
A lactate-induced response to hypoxia.
Taejŏn, South Korea. In Cell, May 2015
The stabilized NDRG3 protein binds c-Raf to mediate hypoxia-induced activation of Raf-ERK pathway, promoting angiogenesis and cell growth.
Overview of fundamental study of pazopanib in cancer.
Tianjin, China. In Thorac Cancer, 2014
In an vitro study, pazopanib exerted anti-tumor effect through mechanisms including the Raf-MAPK/ERK (MEK)-extracellular signal-regulated kinase (ERK) pathway, and directly targeted on v-raf murine sarcoma viral oncogene homolog B (B-raf) as well.
Hepatocellular Cancer: New Kids on the Block.
More papers using
Germany. In Gastrointest Tumors, 2014
PRACTICAL IMPLICATIONS: Although many promising preclinical studies have resulted in phase I-II trials on HCC, so far only the tyrosine and Raf kinase inhibitor sorafenib has made its way into the hands of physicians.
A method for characterising cell death in vitro by combining propidium iodide staining with immunohistochemistry
In BMC Neuroscience, 2001
... Toxin A (Calbiochem, Germany), Raf1 kinase inhibitor (Calbiochem, Germany), manumycin A (Calbiochem, Germany), rapamycin (Calbiochem, Germany), phosphatidylinositol-(3,4,5)-P3 (PIP3,4,5) (Cayman chemical, USA), phosphatidylinositol-(3,4)-P2 (PIP3,4) ... The mechanism of activation of protein kinase C: a biophysical perspective
In Acta Histochemica et Cytochemica, 1991
... Anti-Raf antibody and anti-PKC antibody (α, βI, βII, γ, θ, δ, ɛ, η, ζ, µ) were obtained from Santa Cruz Biotechnology, Inc ...